Haleon Stock News

UBS, the Swiss investment bank, says an early rise in flu incidence could lift 2027 earnings forecasts for Reckitt Benckiser Group PLC (LSE:RKT, OTCQX:RBGLY), the consumer goods group, and Haleon, the consumer health group. The bank rates Reckitt 'buy' with a price target of 7,600p, implying 39% upside from its Monday closing price of 5,484p.

Limited-time experience invites Canadians to explore trusted health solutions, connect with experts and discover practical ways to support their wellbeing Limited-time experience invites Canadians to explore trusted health solutions, connect with experts and discover practical ways to support their wellbeing

Nostalgia-fueled experience introduces Excedrin Rapid Relief, providing fast relief of tough pain that starts in as little as 15 minutes Key Takeaways: Excedrin is introducing My Little Headache, a nostalgic digital-pet experience inspired by the handheld toys of the late '90s and early 2000s, capitalizing on the renewed popularity of digital pets among nostalgia-seeking consumers The interacti...

Unilever PLC (LSE:ULVR) is on JP Morgan's 'positive watch', and Haleon PLC (LSE:HLN, NYSE:HLN) on 'negative watch', ahead of third-quarter reporting by European consumer staples companies. The note adds Givaudan to positive watch alongside Unilever, Heineken N.V.

Haleon PLC (LSE:HLN, NYSE:HLN), the consumer healthcare group, is expected to reduce its 2026 organic sales growth guidance after UBS forecast a subdued third quarter and limited visibility over the cough and cold season. UBS expects Haleon to report organic sales growth of 3.1% for the three months to September, below Visible Alpha consensus of 3.5% and broadly unchanged from the second quarter.

Deutsche Bank has reiterated its 'sell' rating on Haleon PLC (LSE:HLN, NYSE:HLN), warning that the consumer health group faces persistent pressure on growth even as it heads into the cold and flu season. The broker kept a 320p price target on the FTSE 100 company, whose brands include Sensodyne and Panadol, against a last close of 342.8p.

Consumer health company Haleon has achieved growing sales of products to counter side-effects of weight-loss drugs in ​the United States, the company said, capitalising on the rising ‌popularity of GLP-1 medication.

European consumer staples stocks are trading at 18-year lows relative to the broader market, yet Deutsche Bank expects the sector to continue to underperform as consumer spending fails to keep pace with nominal economic growth. Analyst Tom Sykes said the bank has repeatedly tested the hypothesis that staples would recover but continues to expect consumer wallets to lag nominal GDP, putting pres...